Press release
Nosocomial Pneumonia Pipeline, Clinical Trials, FDA Approvals, and Companies 2024 (Updated)
Nosocomial Pneumonia Pipeline
Key Takeaways from the Nosocomial Pneumonia Pipeline Report
• DelveInsight's Nosocomial Pneumonia pipeline report depicts a robust space with 13+ active players working to develop 13+ pipeline therapies for Nosocomial Pneumonia treatment.
• The leading companies working in the Nosocomial Pneumonia Market include Aridis Pharmaceuticals, AstraZeneca, BioVersys, Clarametyx Biosciences, Johnsons & Johnsons Pharmaceutical LLC, PriCara Inc., Merck Sharp & Dohme LLC, Pfizer, Bayer, Nektar Therapeutics, Orlando Health Inc., Medline Industries, Cubist Pharmaceuticals LLC, Peninsula Pharmaceuticals Inc., and others.
• Promising Nosocomial Pneumonia Pipeline Therapies in the various stages of development include Ceftolozane/Tazobactam, meropenem (active comparator), Amikacin inhalation solution (BAY41-6551), and others.
• April 2024:- Pfizer- The purpose of this study is to learn about the safety and effectiveness of Zavicefta once released into the markets in Korea. This study is to learn about Zavicefta in patients with difficult types of infections in the abdomen, urinary tract and pneumonia which could have come from hospitalizations.
• April 2024:- University of Bari- PROACT study aims to resolve uncertainties to influence actual practice guidelines or public health policing regarding VAP prevention in ICU by using probiotics administration. The present study will be a multicenter, randomized, double-blind, placebo-controlled trial. Allocation will rely on a computer-based random number generator provided in a sequentially numbered, sealed, opaque envelope.
Request a sample and discover the recent advances in Nosocomial Pneumonia Treatment Drugs @ Nosocomial Pneumonia Pipeline Report- https://www.delveinsight.com/report-store/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Nosocomial Pneumonia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nosocomial pneumonia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Nosocomial Pneumonia Overview
Nosocomial pneumonia or hospital-acquired pneumonia (HAP) is defined as pneumonia that occurs 48 hours or more after hospital admission and not incubating at the admission time. HAP occurs at a rate of 5 to 10 per 1000 hospital admissions and is considered the most common cause of hospital-acquired infection in Europe and the United States.
Find out more about Nosocomial Pneumonia Therapeutics Assessment @ Nosocomial Pneumonia Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Nosocomial Pneumonia Emerging Drugs Profile
• Tosatoxumab: Aridis Pharmaceuticals
• Suvratoxumab: AstraZeneca
• Rifabutin: BioVersys
• CMTX 101 : Clarametyx Biosciences
Nosocomial Pneumonia Pipeline Therapeutics Assessment
There are approx. 13+ key companies which are developing the Nosocomial Pneumonia therapies. The Nosocomial Pneumonia companies which have their Nosocomial Pneumonia drug candidates in the most advanced stage, i.e. phase III include, Aridis Pharmaceuticals.
DelveInsight's Nosocomial Pneumonia Pipeline Report covers around 13+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Nosocomial Pneumonia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Nosocomial Pneumonia Pipeline Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide
Learn more about the emerging Nosocomial Pneumonia Pipeline Therapies @ Nosocomial Pneumonia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Nosocomial Pneumonia Pipeline Report
• Coverage- Global
• Nosocomial Pneumonia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Nosocomial Pneumonia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Nosocomial Pneumonia Companies- Aridis Pharmaceuticals, AstraZeneca, BioVersys, Clarametyx Biosciences, Johnsons & Johnsons Pharmaceutical LLC, PriCara Inc., Merck Sharp & Dohme LLC, Pfizer, Bayer, Nektar Therapeutics, Orlando Health Inc., Medline Industries, Cubist Pharmaceuticals LLC, Peninsula Pharmaceuticals Inc., and others.
• Nosocomial Pneumonia Pipeline Therapies- Ceftolozane/Tazobactam, meropenem (active comparator), Amikacin inhalation solution (BAY41-6551), and others.
Dive deep into rich insights for new drugs for Nosocomial Pneumonia Treatment, Visit @ Nosocomial Pneumonia Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Nosocomial Pneumonia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Nosocomial Pneumonia- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tosatoxumab: Aridis Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Suvratoxumab: AstraZeneca
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Rifabutin : BioVersys
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. CMTX 101 : Clarametyx Biosciences
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Nosocomial Pneumonia Key Companies
21. Nosocomial Pneumonia Key Products
22. Nosocomial Pneumonia- Unmet Needs
23. Nosocomial Pneumonia- Market Drivers and Barriers
24. Nosocomial Pneumonia- Future Perspectives and Conclusion
25. Nosocomial Pneumonia Analyst Views
26. Nosocomial Pneumonia Key Companies
27. Appendix
For further information on the Nosocomial Pneumonia Pipeline therapeutics, reach out to Nosocomial Pneumonia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
http://demo.advised360.com/read-blog/154799
https://thehealthbridges.com/read-blog/19127
https://app.talkshoe.com/user/joneswilliam/about#google_vignette
https://www.vaca-ps.org/blogs/142022/The-Evolving-Landscape-of-Healthcare-Business-Consulting-Services
https://www.anobii.com/en/01d38d0b9694756e64/profile/activity
https://myanimelist.net/profile/dennydonesgerman
https://forum.pivx.org/threads/healthcare-business-consulting-services-navigating-complexity-in-modern-healthcare.2035/
https://pubhtml5.com/homepage/npvs/
https://b31.org.uk/author/anniesmith9/
https://fairygodboss.com/users/profile/Ix-vMa09gj/Annie-Smith
https://forum.completefrance.com/index.php?/topic/71194-key-areas-of-focus-in-healthcare-consulting-services/
https://educatorpages.com/site/kelleadvin/pages/blog?
https://offgridworld.com/author/anniejones9/
https://www.openhumans.org/member/me/
https://findpenguins.com/5zphebtv0zouo
http://jobs.emiogp.com/author/williamsmith9/
https://www.shippingexplorer.net/en/user/williamsmith9/88249
https://wakelet.com/@DennyDones813
https://startupxplore.com/en/person/denny-dones
https://www.nfpjobs.com.au/employers/1939365-delveinsight
https://community.hodinkee.com/members/dennydoness
https://jobs.mikeroweworks.org/employers/1930150-delveinsight
https://www.social-vape.com/read-blog/132516
https://codex.core77.com/users/dennydones9
https://www.newjerseyhunter.com/members/dennydones1.84566/#about
https://au.blurb.com/user/dennydones9?profile_preview=true
https://trabajo.merca20.com/author/kelleadvin/
https://www.atlasobscura.com/users/dennydones1
https://www.mixcloud.com/dennydones1/
https://www.designspiration.com/ybhardwaj/
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nosocomial Pneumonia Pipeline, Clinical Trials, FDA Approvals, and Companies 2024 (Updated) here
News-ID: 3471751 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Nosocomial
Nosocomial Pneumonia Pipeline: Key Advances and Emerging Therapies Shaping Treat …
The treatment landscape for Nosocomial Pneumonia continues to advance, driven by the urgent need to combat antibiotic resistance and improve patient outcomes in hospital settings. Despite progress with existing antibiotics, challenges such as multidrug-resistant pathogens and limited effective therapies remain critical concerns. Leading pharmaceutical and biotech companies, including Aridis Pharmaceuticals, AstraZeneca, BioVersys, and Clarametyx Biosciences, are actively developing novel antimicrobials and innovative treatment approaches targeting resistant bacteria and optimizing pneumonia…
Strengthening Patient Safety-Innovations and Growth in the Nosocomial Infection …
In the face of escalating healthcare challenges, the global Nosocomial Infection Treatment Market is poised for transformative growth. Nosocomial infections-also known as hospital-acquired infections (HAIs)-affect an estimated 1 in 10 hospitalized patients worldwide, driving prolonged hospital stays, increased healthcare costs, and elevated morbidity. The nosocomial infection treatment market was valued at approximately USD 33.4 billion in 2023 and is anticipated to reach USD 58.9 billion by 2033, growing at a…
Nosocomial Infections Market Size, Industry Analysis 2022
According to Precision Business Insights (PBI) latest report the Global Nosocomial Infections Market is estimated to be valued at USD 4,281.1 million in 2022 and is poised to grow at a significant CAGR of 8.1% over 2022-2028. Global Nosocomial Infections Market by Products (Heat Sterilization Equipment, Low-Temperature Sterilization Equipment, Radiation Sterilization Equipment, Disinfection Equipment), By End Users (Hospitals, Ambulatory Surgical Centre, Medical Institutions, Diagnostic Laboratories, Clinics), and Geography (North America,…
Nosocomial Infection Treatment Market to Witness Robust Expansion by 2024
LP INFORMATION offers a latest published report on Nosocomial Infection Treatment Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Nosocomial Infection Treatment market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.…
New Report: Global Nosocomial Infections Market
MarketResearchReports.Biz presents this most up-to-date research on "Nosocomial Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017"
Report, Nosocomial Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Nosocomial Infections Report is to understand the market and pipeline status of the drugs around the Nosocomial…
Rising Prevalence of Nosocomial Infections and Increased Number of Surgeries to …
Rising Prevalence of Nosocomial Infections and Increased Number of Surgeries to Drive Adoption of Steam Autoclave Systems Globally | Researchmoz.us
Researchmoz added Most up-to-date research on "Steam Autoclave Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024" to its huge collection of research reports.
Autoclaves play a vital role in sterilization of health care waste in hospitals, health care organizations, and academics. Medical devices require autoclaving after…
